Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020867 | 0.80 | SLC6A7 (0.35) | SLC6A7KDM4ECYP2C19MAPK1ALDH1A1 | |
| SCHEMBL14296690 | 0.79 | MAPK1 (0.37) | CYP2C19MAPK1ALDH1A1KMT2AAR | |
| SCHEMBL3649553 | 0.75 | AR (0.41) | KDM4EALDH1A1ARGPR119 | |
| SCHEMBL16909718 | 0.75 | MAPK1 (0.31) | MAPK1AR | |
| SCHEMBL26156915 | 0.72 | KDM4E (0.36) | SLC6A7KDM4ECYP2C19ALDH1A1KMT2A | |
| SCHEMBL18081206 | 0.72 | OPRM1 (0.45) | SLC6A7KDM4ECYP2C19HTR1A | |
| SCHEMBL2847188 | 0.68 | KDM4E (0.43) | SLC6A7KDM4ECYP2C19KMT2AMEN1 | |
| SCHEMBL2847189 | 0.68 | KDM4E (0.43) | SLC6A7KDM4ECYP2C19KMT2AMEN1 | |
| SCHEMBL20009032 | 0.68 | SLC6A7 (0.38) | SLC6A7KDM4ECYP2C19ALDH1A1 | |
| SCHEMBL1024219 | 0.67 | KDM4E (0.41) | SLC6A7KDM4ECYP2C19MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772291-B2 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-1893212-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080139598-A1 | Amine-linked Multicyclic Compounds and Methods of Their Use | LEXICON PHARMACEUTICALS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008058064-A1 | AMINE-LINKED MULTICYCLIC COMPOUNDS AS INHIBITORS OF THE PROLINE TRANSPORTER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | GRIN2C, CHAT, COMT | SLC6A7 1113/4885KDM4E 3142/4885CYP2C19 192/4885 |
| US-20080139598-A1 | Amine-linked Multicyclic Compounds and Methods of Their Use | MAOB, HNMT, MAOA | SLC6A7 607/4885KDM4E 2225/4885CYP2C19 8/4885 |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | SLC6A7 1024/4885KDM4E 2349/4885CYP2C19 4107/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | SLC6A7 746/4885KDM4E 1625/4885CYP2C19 4665/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | SLC6A7 2686/4885KDM4E 1641/4885CYP2C19 4314/4885 |
| US-20060258672-A1 | Multicyclic compounds and methods of their use | GRIN2C, CHAT, COMT | SLC6A7 1113/4885KDM4E 3142/4885CYP2C19 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.